Introduction: Designing a radiation plan that optimally delivers both target coverage
structures when the dose limit is just met, while others may choose to pursue further sparing after the dose limit is met. Automatic and knowledge-based planning aids have been developed with the aim of increasing plan quality while reducing variability.
The variability in plans is particularly true for complex treatment sites such as the head and neck. This region of the body has an abundance of important and radiation sensitive OARs and frequently requires treatments of irregularly shaped planning target volumes (PTVs) with potentially multiple dose prescriptions. One major area of concern for head and neck treatments is the dosimetric sparing of a patient's salivary glands, pharyngeal constrictors, and larynx. High doses of radiation to these organs can cause dry mouth (xerostomia) and difficulty swallowing (dysphagia). [2] [3] [4] [5] [6] Sparing a patient's salivary glands and larynx has been shown to reduce symptoms and increase patient quality of life. 2, [7] [8] [9] The QUANTEC review of dose-volume effects on salivary function by Deasy et al. concluded that for IMRT plans the mean dose to each parotid gland should be kept as low as possible. 3 It also states that, "a lower mean dose to the parotid gland usually results in better function, even for relatively low mean doses (<1000 cGy)." 3 The same review examining larynx and pharynx dosevolume effects had a similar conclusion stating that planners should minimize the volume of pharyngeal constrictors and larynx receiving 6000 cGy, and when, possible 5000 cGy. 6 Both publications emphasize the concept of minimizing the dose to these structures beyond the published/accepted benchmarks (i.e., as low as achievable). However, in practice, it is difficult to determine if a particular plan has in fact minimized the dose to these structures using a dose-volume his- 
| MATERIALS AND METHODS
We identified 10 patients treated on one of two prospective protocols at our institution. All patients had primary lesions of the oropharynx and were node positive. Patients were originally treated using Tomotherapy (Accuray, Palo Alto, USA) (field width = 2.5 cm and pitch = 0.287-0.310) and retrospectively re-planned using Raystation (RaySearch Medical Laboratories AB, Stockholm, Sweden)
on an Elekta Versa HD (Stockholm, Sweden) using volumetric arc therapy (VMAT) with three full 6 MV arcs (re-plan) and four full 6 MV arcs (IQ plan). The re-plan treatments were performed blinded to the results of the clinical plan and PlanIQ Feasibility DVH. For the IQ plan, the results from the PlanIQ Feasibility DVH analysis were available and used during treatment planning.
During planning, the MLC leaf motion was limited to 0.48 cm/degree. The PTVs and OARs used during clinical planning were the same as used during the re-plan and IQ plan. All OARs were expanded by 3 mm and PTVs pulled in skin 3 mm. A combination of equivalent uniform dose (EUD)-and DVH-based planning methods were used. The high risk PTV (PTV HR) was prescribed to 6000 cGy and the standard risk PTV (PTV SR) was prescribed 5400 cGy in 200 cGy fractions.
These two plans were delivered using simultaneous integrated boost (SIB). For the re-plan, a multi-criteria optimization (MCO) was generated for each patient followed by conversion to a deliverable plan and additional manual optimization. EUD optimization was used for sparing of OARs. Optimization structures were used for each OAR by subtracting the PTV SR with a 3 mm margin from the OAR. A maximum EUD (equation below) equal to 100-200 cGy less than the current average dose was used as a constraint with the "a" parameter equal to one prior to each round of optimizations.
where v i is the partial volume with absorbed dose D i .
This process was repeated until additional sparing was not achieved or sparing resulted in other plan issues such as hot spots, failing of clinical goals, etc. that could not be recovered. The goal of the re-plan was to maximally spare the contralateral parotid, contralateral submandibular gland, and larynx while still meeting our routinely used clinical goal sheet (Table 1) . For the IQ plan, the Sun Nuclear PlanIQ Feasibility DVH information was made available during the planning process. The same (MCO) was performed; however, rather than iteratively reducing the optimization constraints for the OARs, the mean value derived from the impossible DVH was used as the criteria for the max EUD with the "a" parameter equal to one.
The EUD with the "a" parameter equal to one is equivalent to the mean dose. The re-plan was performed blinded to the results of the clinically delivered plan as well as the Feasibility DVH information from PlanIQ. The IQ plans were performed aware of the Feasibility DVH information. The IQ plans were not compared to the clinically delivered plan nor the re-plan during the planning process. A summary of the generated plans is shown in Table 2 .
The Feasibility DVHs were generated by exporting the simulation CT and patient structures to PlanIQ. In PlanIQ, the PTVs were assigned their respective prescription doses and the Feasibility DVHs were calculated for 6 MV beams and a dose grid size of 2 mm using the maximal falloff method. The Feasibility DVHs are calculated using energy-specific high gradient dose spread (HGDS) kernel assuming the entire PTV is receiving prescription. All neighboring voxels within a distance determined by the HGDS are searched, and if they are target surface voxels, their distance away (or radiological distance, if heterogeneity corrections are employed) and dose level produce a dose spread value at all nontarget voxels. A low dose spread (LDS) process adds a minimal low dose that must occur due to scatter and transmission assuming beams from many angles, 360°around the targets. Again, on a voxel-by-voxel basis, it estimates a minimal dose that must occur at any given voxel outside the targets, assuming 100% coverage and given the target sizes, shapes, and dose levels. Two low dose spread kernels are generated dynamically (based on nominal energy and target volume), one for near and far distances, and are used to convolve the original 3D target doses into two low dose 3D grids. There is energy-dependent postprocessing of each LDS grid to further morph the lower dose values and to apply corrections in regions of low patient density. Then, for each LDS grid and for each nontarget voxel, the LDS value is compared to the current dose using the HGDS at all voxels, and if it is higher, then it replaces the current value in the benchmark grid. PlanIQ does not require any knowledge about the delivery technique or commissioning data. paired Wilcoxon sign rank test was used to determine statistical significance between plans. A Bonferroni correction was used in order to account for multiple hypothesis testing (P < 0.008 was needed for significance).
All plans were determined if they would be "clinically deliverable"
by the attending physician for these patients. The process of determining clinical deliverability was performed in the same manner as initial approval in that the physician reviewed the plan in all slices examining both DVH constraints as well as overall plan quality (i.e., no obvious hotspots outside the PTVs, reduced dose to the posterior neck and oral avoidances, etc.). To ensure that the generated plans were deliverable, our clinical IMRT QA procedure was performed on all IQ plans. A 3D diode array (ArcCHECK, Sun Nuclear, Melbourne, FL) was used to measure the machine delivered dose and SNC patient software (version 6.1.0; Sun Nuclear, Melbourne, FL, USA) was used to calculate the gamma pass rate using a global criteria of 3%/3 mm. At our institution, the standard criteria pass rate that we deem a plan acceptable for treatment is greater than 90%.
| RESULTS
All plans passed our institutional IMRT QA standard (range: 92.8%-98.6%). The comparison between the mean dose from the clinical, re-plan, and IQ plans to the impossible boundary from the Feasibility DVH (Impossible DVH) are shown in Fig. 1 . The re-plans were able to provide increased sparing of OARs compared to the delivered plans and subsequently agreed better with the mean dose from Impossible DVH. The contralateral parotid and larynx were spared for all patients in both the clinically delivered plan and the re-plan.
On average, the re-plan reduced the dose compared to the clinical plan by approximately 750 cGy and 600 cGy for the contralateral parotid and larynx, respectively. For patients whose contralateral submandibular gland was spared in the clinical plan (7/10 patients), the re-plans reduced the mean dose by approximately 300 cGy.
The IQ plans were found to reduce the mean dose to the con- Reducing the dose to the contralateral parotid and larynx bỹ 1200 cGy could potentially lead to a meaningful improvement in patient toxicity/symptom burden.
This study demonstrates that planners could use the Feasibility DVH to guide dosimetric constraints during planning to ensure plans have been adequately optimized. Overall, the average difference between re-planned and impossible DVH was found to be within 200-700 cGy for the salivary glands and larynx when blinded to PlanIQ's Feasibility DVH and approximately 100 cGy when this information is available during planning. The achieved doses were sometimes less than the Impossible DVH; however, this was found to be due to under dosing of the PTV (predominantly the PTV SR).
As our routine prescription is to 95% coverage of PTVs, under dosing is permitted in OAR overlap regions while planning, but not accounted for in PlanIQ. This is why the re-planned contralateral submandibular mean doses fall below the predicted impossible mean. | 249 institution has subsequently has shifted to predominantly using Raystation and therefore this was of more clinical interest. were delivered with more homogeneous target doses and better low dose conformity, whereas the IQ plans had superior OAR sparing but more heterogeneous target doses and inferior low dose conformity in certain areas. Our institution is a high volume, academic center that is an active participant in head and neck clinical trials.
Despite these credentials, we were surprised to see how much higher our OAR doses were compared to those predicted by PlanIQ.
Subsequently, the IQ plans were able to demonstrate that these predictions were quite accurate in terms of what could be delivered.
These results have led us to begin incorporating PlanIQ into our routine clinical planning processes.
In the future, our institution hopes to continue to utilize PlanIQ and to standardize methods by which this information is incorporated into the planning process. While we utilized 3 and 4-arc VMAT for this research, we have yet to determine if similar plans could be generated with few arcs in order to optimize clinical throughput. We also intend to investigate whether PlanIQ can not only improve plan quality but also if it may result in a reduction of planning time by providing reasonable estimates of expected DVHs upfront in the planning process. Evaluation of PlanIQ needs to be performed for sites other than head and neck.
Tools capable of providing predictions of what is dosimetrically achievable (and ideally optimal) are greatly needed in radiation treatment planning in order to reduce plan variability and ensure quality.
This work demonstrates for the first time that PlanIQ's Feasibility DVH agrees well with head and neck treatment plans that attempted to maximally spare salivary glands and the larynx. The addition of the Feasibility DVH information during planning led to an increased sparing of OARs compared to both clinical plans and plans blinded to this information. This suggests the Feasibility DVH could be a useful tool during planning and as a plan quality assurance tool. In the future, quantitative predictions such as the Feasibility DVH may be used in tandem with knowledge-based or auto-planning to provide the best of both worlds in terms of a tool that can address Feasibility, optimality, and deliverability. Additional studies are needed examining the incorporation of Feasibility DVHs during treatment planning and whether it could also lead to increases in clinical efficiency.
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